Loading
Vaccine Coverage and Hesitancy · Review
Health Science Reports · July 27, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes the role of pharmacists in mpox response across clinical care, vaccine management, supply chain resilience, and public health surveillance. It identifies systemic barriers—including vaccine inequities, inadequate training, and limited outbreak planning involvement—and recommends structural reforms and multidisciplinary integration to strengthen health system preparedness. The work is expert commentary rather than primary evidence of intervention efficacy.
Narrative review. Global populations affected by mpox, with emphasis on vaccine access inequities in Africa; health systems and pharmacy workforces..
In Africa, 1.2 billion people lack access to mpox vaccines, an inequity that pharmacists can address through community outreach and trust-building. Pharmacists can strengthen supply chains through inventory management, local production, and emerging technologies such as artificial intelligence, blockchain, and continuous manufacturing. Pharmacist impact is limited by vaccine inequities, varying clinical authority, inadequate training, and limited involvement in outbreak planning.
No quantitative data on efficacy or effectiveness of pharmacist interventions in mpox management are presented. No comparative analysis of pharmacist impact across different health systems or regions is provided.
Clinicians and health administrators should consider integrating pharmacists into multidisciplinary outbreak response teams and investing in their training in pharmacovigilance and infectious disease management to enhance pandemic preparedness and cost-effectiveness. The review identifies structural barriers to pharmacist engagement that require policy and organisational change.
A narrative review synthesizing literature on pharmacist roles in mpox management, offering expert recommendations for health system integration rather than reporting primary evidence of clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and health administrators should consider integrating pharmacists into multidisciplinary outbreak response teams and investing in their training in pharmacovigilance and infectious disease management to enhance pandemic preparedness and cost-effectiveness. The review identifies structural barriers to pharmacist engagement that require policy and organisational change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background and Aims: Pharmacists play a key role in managing and mitigating mpox through clinical care, pharmacovigilance, vaccine management, and resilient supply chains. Management focuses on supportive care, infection prevention, and accurate diagnosis, with pharmacists ensuring the availability and rational use of vaccines, disinfectants, laboratory reagents, and personal protective equipment. They also promote vaccine equity, community engagement, pharmacovigilance, and efficient production and distribution of health commodities. In Africa, where 1.2 billion people lack access to mpox vaccines, pharmacists help address inequities through community outreach and trust-building. They further strengthen supply chains using inventory management, local production, and technologies such as artificial intelligence, blockchain, and continuous manufacturing. Pharmacists support humanitarian supply chains by promoting rational medicine use, preventing antimicrobial resistance, and supporting adherence. However, their impact is limited by vaccine inequities, varying clinical authority, inadequate training, and limited involvement in outbreak planning. Expanding their roles in surveillance, pharmacoeconomics, and real-world evidence is crucial to improve outcomes and cost-effectiveness. Looking ahead, pharmacists are essential in smallpox and mpox vaccine research, contributing to safety and efficacy through involvement in drug development and clinical trials. Methods: This narrative review employs a thematic synthesis to evaluate the pharmacist's role in the global mpox response. By analyzing literature from major databases (PubMed, Scopus, and Google Scholar) and technical reports, it identifies systemic opportunities and structural challenges within the pharmaceutical lifecycle. Conclusion: Integrating pharmacists into multidisciplinary teams and enhancing their training in pharmacovigilance and infectious disease management are critical to achieving sustainable outbreak preparedness. Empowering pharmacists through structural reforms can enhance health system resilience, optimize cost, and safeguard public health in current and future pandemics.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.